Related Experiment Video
Updated: Dec 20, 2025
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
Published on: March 18, 2014
HER2-Targeted Therapy in Osteosarcoma
Jonathan Gill1, Pooja Hingorani1, Michael Roth1
1Division of Pediatrics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Abstract:
In this chapter, we will review studies of HER2 in osteosarcoma and discuss the controversies that have existed in this field. Our present understanding of HER2 in the context of osteosarcoma is that it is expressed on a subset of patient samples, but that expression is not prognostic. We will review the two trials that have been conducted in osteosarcoma which have targeted HER2. Use of an antibody, trastuzumab, did not suggest activity, but a smaller study using HER2-targeted CAR T cells suggested activity may be present. A trial of an antibody-drug conjugate targeting HER2 for recurrent osteosarcoma is under consideration. Trials targeting other surface proteins for the treatment of osteosarcoma have occurred or are in development. Indeed, this leads us to discuss in a broader fashion therapeutic approaches to targeting surface proteins. It is hoped that some of these approaches will lead to new effective therapies for patients with osteosarcoma.
Insights
HER2 (Human Epidermal growth factor Receptor 2) is expressed in some osteosarcoma patients but isn't prognostic. HER2-targeted therapies show mixed results, with CAR T-cells suggesting promise for osteosarcoma treatment.
Area of Science:
- Oncology
- Molecular Biology
- Immunotherapy
Background:
- Human Epidermal growth factor Receptor 2 (HER2) is a protein implicated in various cancers.
- Its role and prognostic significance in osteosarcoma remain subjects of investigation and debate.
- Understanding HER2 expression is crucial for developing targeted therapies in osteosarcoma.
Purpose of the Study:
- To review existing studies on HER2 in osteosarcoma.
- To discuss controversies surrounding HER2 expression and its prognostic value.
- To evaluate the efficacy of HER2-targeted therapeutic approaches in osteosarcoma.
Main Methods:
- Review of clinical trials and studies investigating HER2 in osteosarcoma.
- Analysis of data from trials using trastuzumab (antibody) and HER2-targeted CAR T-cells.
- Discussion of ongoing and proposed trials, including antibody-drug conjugates.
Main Results:
- HER2 is expressed in a subset of osteosarcoma patient samples, but this expression is not considered prognostic.
- Trastuzumab (an antibody) showed no significant activity in osteosarcoma trials.
- A smaller study indicated potential activity for HER2-targeted CAR T-cells in osteosarcoma.
Conclusions:
- HER2-targeted therapies in osteosarcoma have yielded mixed results.
- HER2-targeted CAR T-cells show preliminary promise, warranting further investigation.
- Broader strategies targeting surface proteins may offer new therapeutic avenues for osteosarcoma.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistant Cancers
01:27Tumor Immunotherapy